Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia by Parhofer, Klaus G
© 2009 Parhofer, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 901–908
Vascular Health and Risk Management
901
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Review of extended-release niacin/laropiprant 
fixed combination in the treatment of mixed 
dyslipidemia and primary hypercholesterolemia
Klaus G Parhofer
Medical Department ii Grosshadern, 
University of Munich, Germany
Correspondence: Klaus G Parhofer  
Medical Department ii _ Grosshadern, 
University Munich, Marchioninistr. 
15, 81377 Munich, Germany 
Tel +49 89-7095-3010 
Fax +49-89-7095-8879 
email klaus.parhofer@med. 
uni-muenchen.de
Abstract: Although statins reduce cardiovascular morbidity and mortality further risk 
reduction is needed. In this respect low HDL-cholesterol concentrations and/or elevated triglyc-
eride concentrations may be potential treatment targets. Niacin (nicotinic acid) is an effective 
drug which increases the plasma concentration of high-density lipoprotein (HDL)-cholesterol 
and decreases the concentration of low-density lipoprotein (LDL)-cholesterol, triglycerides and 
lipoprotein(a). Clinical studies indicate that niacin can significantly reduce the risk for cardio-
vascular events. However, niacin is not very commonly used because of significant side effects 
(especially flushing). Laropiprant is a potent selective antagonist of PGD2-receptor subtype-1 
and can thus reduce niacin-induced flushing. Although the addition of laropiprant will reduce 
the frequency of flushing, it will not completely eliminate this side effect. Laropiprant does not 
change the effect of niacin on lipids or other side effects of niacin (ie, gastro-intestinal problems, 
glucose elevation). The combination of niacin with laropiprant may therefore enable use of niacin 
at higher doses and therefore exploit the full potential of the drug. Endpoint studies that will be 
published over the next few years will show whether this treatment modality also translates into 
clinical effect in patients treated with statins. Until publication of these studies niacin/laropiprant 
should be used only in high-risk patients not achieving lipid goals on statins.
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Introduction
Atherosclerosis and its complications such as myocardial infarction, stroke and 
peripheral vascular disease remain important reasons of mortality and morbidity 
in industrialized and developing countries.1 Therefore, it is of utmost importance 
to develop strategies for treating and preventing atherosclerosis. Atherosclerosis is 
seen as a dynamic process which is initiated and maintained by the interaction of risk 
factors and immunologic processes.2 While many risk factors such as dyslipidemia, 
diabetes, smoking and hypertension are well established the mechanisms linking these 
risk factors with atherosclerosis are less well known.
Therefore, strategies to reduce risk factors are still our most powerful tools to pre-
vent and treat atherosclerosis. Although many approaches have been proven successful, 
the treatment of dyslipidemia is probably the one which mediates the biggest benefit. 
Most of our current strategies with respect to lipids focus on low-density lipoprotein 
(LDL)-cholesterol reduction. This relates to several aspects. First, the mechanism by 
which elevated concentrations of LDL-particles result in atherosclerosis is relatively 
well understood. Especially after oxidation and/or modification LDL particles are 
central for inducing the immunologic processes underlying atherosclerosis. Second, the Vascular Health and Risk Management 2009:5 902
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epidemiological relationship between elevated total cholesterol 
and atherosclerosis can be attributed to a large extent to elevated 
LDL-cholesterol. Finally, many studies have shown that low-
ering LDL-cholesterol by statins or other forms of therapy 
can reduce morbidity and mortality from atherosclerosis.3,4
The importance of treating abnormal lipid concentrations 
to prevent atherosclerotic events is also reflected in the guide-
lines of professional associations such as the American Heart 
Assocation, European Society of Cardiology and others.5,6 
These guidelines have focused on LDL-cholesterol reduction 
although over the last decade it has been recognized that tri-
glycerides, high-density lipoprotein (HDL)-cholesterol, and 
lipoprotein(a) are not only important as predictors of athero-
sclerotic events but are potential therapeutic targets.7 This is 
very important since LDL-lowering strategies can obviously 
not prevent all atherosclerotic events. In fact, most studies 
report a relative risk reduction of 25% to 35%, which means 
that on average the majority of events cannot be prevented.3,4 
Several strategies can be developed to improve this result. It 
is conceivable that more aggressive LDL-cholesterol reduc-
tion might further prevent atherosclerotic events. Another 
approach would be to address other lipidologic risk factors, 
such as triglycerides, HDL-cholesterol, lipoprotein(a), and 
probably also postprandial lipoproteins and specific subfrac-
tions of LDL and/or HDL.
Current treatment strategies  
and its limitations
The current treatment strategy strongly focuses on LDL-
cholesterol reduction (Table 1). Depending on the absolute risk, 
an LDL-cholesterol of 100 mg/dL (optional 70 mg/dL) 
in patients with high risk (ie, 20% event rate/10 years) or 
an LDL-cholesterol 130 mg/dL (intermediate risk) or an 
LDL-cholesterol 160 mg/dL (low risk) is set as a treatment 
goal.5 The primary drug treatment used to achieve these 
goals is usually a statin. However, several other drugs are 
available to modify lipid levels. These drugs differ in mode 
of action, effect on lipids and degree of evidence with respect 
to reducing cardiovascular morbidity and mortality. Table 2 
summarizes the various lipid-modifying drugs.
In patients with normal triglyceride and HDL-cholesterol 
levels but elevated LDL-cholesterol levels despite statin ther-
apy several approaches are possible. These include increas-
ing the dose of the statin, switching to a more potent statin, 
combining the statin with a cholesterol absorption inhibitor 
(ezetimibe) or combining a statin with a bile acid binding 
compound (for example colesevelam). For patients on a 
statin with abnormal triglyceride and/or HDL-cholesterol 
concentrations combination therapy of a statin with niacin 
may be a treatment option. The combination of statins with 
either a fibrate or omega-3 fatty acids may be alternatives. In 
patients with isolated hypertriglyceridemia primary fibrate 
or niacin therapy or treatment with omega-3 fatty acids may 
be considered.
However, it must be acknowledged that not all treatment 
strategies are covered by convincing end point data and some 
of the suggested combination therapies are associated with 
considerable side effects. This is particularly true for the 
combination of a statin with niacin or with a fibrate.
Niacin (nicotinic acid)
Niacin was the first lipid-lowering drug developed.8 Despite 
clear lipid-lowering effects and the proof of clinical benefit 
in early prevention studies, niacin is not used very often in 
clinical practice. There are multiple reasons, the most impor-
tant being the high rate of side effects and the stronger LDL-
cholesterol reduction and the better documented effects of 
statins.4,9 Although extended-release forms of niacin (ERN) 
have somewhat less side effects in clinical practice, niacin 
is rarely used.
Table 1 Low-density lipoprotein (LDL) goals in different patient groups5
Risk group LDL cholesterol goal Threshold for drug therapy
High risk (CAD or CAD equivalent: peripheral  
vascular disease, abdominal aortic aneurysm,  
cerebrovascular disease, diabetes) 10-year  
risk 20%
100 mg/dL (2.6 mmol/L) optional:  
70 mg/dL (1.8 mmol/L)
100 mg/dL (2.6 mmol/L)
Moderately high risk: 2 risk factors 10-year  
risk 10%–20%
130 mg/dL (3.4 mmol/L) 130 mg/dL (3.4 mmol/L)
Moderate risk 2 risk factors  
10 year risk 10%
130 mg/dL (3.4 mmol/L) 160 mg/dL (4.1 mmol/L)
Lower risk 1 risk factor 160 mg/dL (4.1 mmol/L) 190 mg/dL (4.9 mmol/L)
Notes: Risk factors: smoking, hypertension, low HDL-cholesterol (40 mg/dL), positive family history for premature CAD (men  55 years, women  65 years), age 
(men  45 years, women  55 years).
Abbreviations: CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.Vascular Health and Risk Management 2009:5 903
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Effect of niacin on lipids
The effects of niacin on plasma lipids depend on the dose 
and the underlying dyslipoproteinemia. Clinically significant 
changes of lipid levels are usually seen at doses of 1 g/day 
or higher, but doses of 1.5 g/day or 2 g/day are neces-
sary to achieve the full effect on lipids. Generally, niacin 
decreases total cholesterol, triglycerides, LDL-cholesterol 
and lipoprotein(a), while it increases HDL-cholesterol.10,11 
The effects of niacin are summarized in Table 3.
Although niacin was initially used as monotherapy or in 
combination with fibrates or bile acid binding compounds, 
nowadays it is primarily indicated in combination with 
statins.12,13 It is therefore important to evaluate whether the 
changes described above also hold true in patients on statin 
therapy. In a recent study comparing 4 treatment arms in 
293 patients with dyslipidemia it was shown that rosuvastatin 
(40 mg/day), simvastatin with ezetimibe (40 mg/10 mg per 
day), rosuvastatin with niacin (20 mg/2000 mg per day), and 
atorvastatin with niacin (40 mg/2000 mg per day) resulted in 
an identical reduction of LDL-cholesterol (–50% to –55%). 
Therapies without niacin resulted in an increase of HDL-
cholesterol of approximately 5% to 10%, while the increase in 
combination therapy using niacin was 22% to 25%. In addition, 
combinations using niacin decreased triglycerides by 40% to 
50%.14 This indicates that the effect of niacin on plasma lipids 
is independent of the underlying baseline medication.
Generally it can be assumed that niacin at a dose of more 
than 1.5 g/day will decrease LDL-cholesterol, triglycerides 
and lipoprotein(a) by approximately 20%, while it will 
increase HDL-cholesterol also by approximately 20% (“rule 
of 20%”).9,15
Mechanism of action of niacin
The mechanism by which niacin affects plasma lipids is not 
completely understood.16 Niacin binds to a specific G-protein 
receptor (GPR109A) which is expressed in adipose tissue 
and in epidermal cells.17 The binding of niacin to the receptor 
results in a decreased lipolysis and thus a dose-dependent 
decreased release of free fatty acids into plasma. This 
decrease is followed by a rebound.18 Despite this rebound 
the decreased flow of free fatty acids to the liver results in a 
decreased secretion of very low-density lipoprotein (VLDL) 
particles.19 Hepatic VLDL secretion is determined by a 
number of regulators, of which free fatty acid concentration 
is probably the most important. The changes in LDL con-
centration and thus LDL-cholesterol are probably secondary 
phenomena. Since LDL are to a large extent the metabolic 
product of VLDL delipidation, it is evident that a decreased 
VLDL secretion rate will also reduce concentration of LDL 
particles. Niacin also affects the LDL subtype distribution, 
resulting in a shift from small dense LDL particles to more 
buoyant lipoproteins.20 This results in less atherogenic 
LDL particles. For HDL-cholesterol, it is believed that the 
deceased concentration of VLDL particles will result in a 
decreased interaction with HDL particles leading to higher 
HDL-cholesterol concentrations. Whether and to what extent 
direct effects on HDL metabolism are important in inducing 
the raise in HDL-cholesterol is unknown. Furthermore, niacin 
also results in a shift within the HDL fraction; thus the HDL2:
HDL3 ratio is increased. Again this is considered beneficial 
Table 3 effect of nicotinic acid on lipids, lipoprotein and apoproteins
Lipoprotein class Effects
Apo B-containing lipoproteins VLDL ↓
iDL ↓
LDL ↓
Apo B ↓
Small-dense LDL ↓
Lp(a) ↓
Apo A-containing lipoproteins HDL ↑
HDL2 ↑
HDL3 ∼
Apo A-i ↑
important ratios Total cholesterol/ 
HDL cholesterol ↓
LDL-cholesterol/ 
HDL cholesterol ↓
Apo B/Apo A-i ↓
HDL2/HDL3↑
Lp A-i/Lp A-i + 
A-ii ↑
Abbreviations: Apo, apoprotein; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; Lp, lipoprotein;   VLDL, very low-density lipoprotein.
Table 2 effect of lipid-modifying drugs
Lipid effect Effect on 
morbidity/
mortality
Statins LDL ↓↓↓,   TG ↓ ++++/-
Fibrates TG ↓↓↓, HDL ↑, LDL ↓ +/-
Nicotinic  
acid/niacin
LDL ↓↓,   TG ↓↓, HDL ↑↑ +
Cholesterol  
adsorption inhibitors
LDL ↓↓ 0
Bile acid binding resins LDL ↓↓,   TG ↑ +
Omega-3-fatty acids TG ↓↓, HDL ↑ 0/(+)
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, 
total triglycerides.Vascular Health and Risk Management 2009:5 904
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in relation to atherosclerosis. The mechanism underlying 
the reduction of lipoprotein(a) during therapy with niacin 
is unknown. However, it is an interesting observation that 
lipoprotein(a) concentrations can be decreased only by drugs 
that affect lipoprotein production, such as niacin or apo B 
antisense oligo-nucleotides such as mipomersen.21 Drugs that 
primarily affect the catabolism of lipoproteins, such as statins, 
ezetimibe, or bile acid-binding compounds, usually have no 
effect on lipoprotein(a) concentration. Whether and to what 
extent niacin affects postprandial lipoprotein metabolism is 
unknown. However, it can be assumed that niacin will not 
only improve fasting lipids but also postprandial lipoprotein 
metabolism.
Clinical studies with niacin
A number of studies have shown that niacin can decrease 
surrogate parameters of atherosclerosis and clinical events 
(Table 4).12,22–26 The HATS trial tested the hypothesis that 
lipid-modifying (simvastatin and niacin) and antioxidant 
therapy provide independent and additive benefits for patients 
with coronary heart disease and low HDL-cholesterol.22 
The study compared placebo vs simvastatin/niacin vs anti-
oxidants vs simvastatin/niacin with antioxidants. The study 
showed no effect of antioxidants but proved that patients 
receiving simvastatin in combination with niacin had a sig-
nificant reduction in cardiovascular events (60% relative risk 
reduction for simvastatin/niacin vs no simvastatin/niacin). 
However, as in previous studies it was not tested whether 
niacin provides an additional effect over statin monotherapy. 
The extent of risk reduction (60%) indicates, however, that 
the effect is more prominent than could be expected by 
simvastatin alone.
The coronary drug project evaluated the effect of niacin 
as monotherapy in patients with established coronary heart 
disease.11 After 6 years of treatment the clinical event rate 
was decreased by 27% in the niacin group. Furthermore, 
a secondary analysis (after 15 years) showed a decrease in 
total mortality of 11%.23
Side effects of niacin
Despite these convincing data on lipids and clinical events, 
niacin is not very often used in clinical practice because 
of side effects. However, not all studies report high rates 
of discontinuation.27–29 Although the rate of flushing was 
decreased by using slow-release formulations it stills repre-
sents a hurdle for its clinical use. Furthermore, gastrointesti-
nal symptoms such as diarrhea, nausea and reduced appetite 
as well as elevated glucose concentrations were reported.
In humans the flush following the oral intake of niacin is 
the result of a cutaneous vasodilatation which is mediated by 
prostaglandin D2 (PGD2).30 In the skin niacin binds to the 
same receptor that mediates the lipid-modulating effects. In 
Langerhans cells of the epidermis this binding induces the 
formation of PDG2 which then binds to a specific recep-
tor (prostaglandin-D2-receptor-1). This receptor mediates 
vasodilation and thus flushing.31 In humans this receptor is 
present in the vessels of the skin, in the small intestine, in 
the brain and in the lung.31,32 Acetylsalicylic acid and other 
nonsteroidal anti-inflammatory drugs (NSAID)s have been 
found to have some efficacy suppressing niacin-induced 
Table 4 Selected randomized controlled trials of nicotinic acid12,22–26
Study Intervention Patients receiving 
treatment/total
Change in lipids % Duration years Outcome
CDP (1975) Nicotinic acid 1119/8341 Chol –10  
TG –26  
HDL NR  
LDL NR
6 Decreased nonfatal Mi
CDP follow up (1986) Nicotinic acid 1119/8341 See above 15 Decreased total mortality
CLAS (1987) Nicotinic acid +  
colestipol
80/162 HDL +37  
LDL –43  
TG –22
2 Decreased coronary atherosclerosis  
on angiography (P = 0.002)
HATS (2001) Nicotinic acid +  
simvastatin
38/160 HDL +26  
LDL –42  
TG –36
3 Decreased MACE (first event: death,  
Mi, stroke, revascularization)
ARBiTeR 2 (2004) Nicotinic acid +  
statin
87/167 HDL +21  
LDL –3  
TG –13
1 Decreased progression of carotid iMT   
(P = 0.08); significant in patients with  
insulin resistance
Abbreviations: HDL, high-density lipoprotein; iMT, intima-media thickness; LDL, low-density lipoprotein; MACe, major adverse cardiovascular events; Mi, myocardial infarc-
tion; NR, no result;   TG, total triglycerides.Vascular Health and Risk Management 2009:5 905
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flushing by preventing the production of prostaglandins.33–35 
It is important to realize that the same receptor (GPR109A) 
is responsible for the effect on lipids and the flushing.17 
Strategies addressing the flushing therefore cannot act on 
the niacin receptor since this would also eliminate the effect 
on lipids.
Another important side effect of niacin therapy is the 
induction of elevated glucose concentrations. This was 
observed in earlier studies as well as in newer trials. The 
underlying mechanisms are not understood, but may be 
related to the primary effect on free fatty acid metabolism and 
thus reflect insulin resistance. In most patients the effect on 
glucose metabolism is negligible. In patients with metabolic 
syndrome and borderline disturbances of glucose metabo-
lism such as impaired fasting glucose or glucose intolerance 
however this may be relevant. In a study in diabetic patients 
16 weeks of therapy with 1500 mg/day niacin induced only 
minor changes of fasting glucose concentrations and HbA1c. 
However, during the course of the study oral anti-diabetic 
medication and insulin dose was adjusted.36 Whether the 
effect of niacin on glucose metabolism is clinically relevant 
is questionable since in the Coronary Drug Project patients 
benefitted from such therapy irrespective of baseline glucose 
level.37
Laropiprant
Since the flush induced by niacin is primarily mediated 
through the interaction of prostaglandin D2 with a spe-
cific receptor (prostaglandin-D2-receptor-1) a selective 
antagonist of this receptor was developed (MK-0524, 
laropiprant).38,39 Laropiprant was initially developed as a 
treatment for allergic rhinitis.39,40 It is eliminated primar-
ily after glucuronidation through the liver.41 A small part 
of laropiprant is metabolized through cytochromP450 
3A4. Laropiprant is highly selective for the prostaglandin 
D2-receptor-1. It can be assumed that inhibition of this 
receptor does not reduce the production of prostaglandins, 
but inhibits the vasodilatation following the formation of 
PGD2. Although laropiprant is a potent inhibitor of prosta-
glandin D2-receptor-1, it does not eliminate flushing in all 
patients. Higher doses of laropiprant or concomitant use of 
aspirin or NSAIDs cannot reduce this residual flushing.42,43 
Probably other mediators such as PGE2 and serotonin, as 
well as their pathways, such as the beta-arrestin1/MAP 
kinase signaling pathway, are involved in this residual 
flushing.17,44
Laropiprant can also bind to the thromboxan-A2-receptor, 
which plays an important role thrombocyte function.45 
However, in doses currently used to prevent flushing 
associated with niacin no clinical effects on bleeding or 
thrombocyte function were observed. The current, albeit 
short-term, studies indicate that laropiprant does not affect 
the lipid-modifying properties of niacin and has little side-
effects by its own. However, long-term observations are 
necessary to truly confirm long-term safety. It should also 
be noted that preliminary data indicate that other forms of 
flushing cannot be prevented by laropiprant.
Niacin/laropiprant
Since niacin is associated with flushing and since laropip-
rant can significantly reduce this flushing, it seems obvi-
ous to combine these drugs.46 Recently it was shown that 
the rate of moderate/severe flushing can be reduced from 
50% to 24% by adding laropiprant to niacin.47 The same 
study showed that besides severity also frequency of flush-
ing was reduced. Furthermore, it was recently shown in 
abstract form in a study involving more than 4700 patients 
that the addition of laropiprant to ERN reduced the rate of 
discontinuation due to flushing from 16.6% to 7.2% and 
the overall discontinuation rate from 31.5% to 25.3%.48 
ERN/laropiprant patients use considerably less aspirin/
NSAID to reduce flushing compared to ERN patients 
(11% vs 22%).46
The addition of laropiprant does not change the effect 
of niacin on lipids.49,50 In a study evaluating more than 
1300 patients, niacin with or without laropiprant decreased 
LDL-cholesterol by 18.4%, triglycerides by 25.8% and 
increased HDL-cholesterol by 20%.49 For none of the 
lipid parameters the effect was altered by the addition of 
laropiprant.
In studies evaluating the combination of niacin with 
laropiprant on flushing it was shown that the rate of flushing 
was significantly decreased compared to patients on niacin 
without laropiprant.46–49,51 In the group using additional laro-
piprant the rate of flushing was decreased to placebo level 
after approximately 3 months while it remained elevated in 
patients using niacin without laropiprant.
In a recent post hoc analysis it was also shown that nia-
cin alone or in combination with laropiprant was associated 
with significant placebo-adjusted reductions from baseline in 
blood pressure in hypertensive or normotensive subjects with 
dyslipidemia.52 This may be important since it would indicate 
that niacin not only addresses dyslipidemia as an important 
cardiovascular risk factor, but has a more general beneficial 
effect on risk factors. Acute administration of niacin may 
lower blood pressure because of acute vasodilatory effects. Vascular Health and Risk Management 2009:5 906
Parhofer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
From a chronic perspective, larger studies, such as the 
coronary drug project, suggest that niacin may lower blood 
pressure when administered over a longer period of time. 
Post hoc analyses of some of the more recent trials support 
a chronic, dose-dependent, blood pressure-lowering effect 
of niacin. Since, however, laropiprant does not attenuate 
niacin’s blood pressure-lowering effects, it is unlikely that the 
chronic lowering of blood pressure is due to dilation of skin 
vessels through activation of the prostaglandin receptor.53
Clinical use of niacin/laropiprant
This combination may be used in patients who are considered 
candidates for niacin therapy. The addition of laropiprant 
does not alter the lipid effects but may allow using the doses 
necessary to achieve the full effect of niacin.
Primary candidates are patients with high risk (ie, 20% 
over 10 years) who for multiple reasons do not reach lipid 
goals. Thus, this combination should be considered in 
patients who despite statin therapy have elevated LDL-
cholesterol in combination with elevated triglycerides and/or 
low HDL-cholesterol. Many of the potential candidates 
will have suboptimal LDL-cholesterol, triglycerides and 
HDL-cholesterol despite established vascular disease. 
Furthermore, many potential patients may be diabetic or 
suffer from metabolic syndrome. Niacin/laropiprant may 
also be a treatment option in patients who are at goal with 
LDL-cholesterol but have abnormal HDL-cholesterol and 
triglyceride concentrations (Figure 1).
The role of nicotinic acid/laropiprant is probably less 
clear in patients with isolated severe hypertriglyceridemia 
or patients with isolated LDL hypercholesterolemia. In those 
patients other treatment modalities are possible. Thus, in 
patients with isolated severe hypertriglyceridemia, lifestyle 
changes, which are of utmost importance, may be combined 
with fibrates, niacin/laropiprant, omega-3 fatty acids or rarely 
statins. In selected patients combinations of these drugs 
may be necessary. Similarly in patients with isolated LDL 
hypercholesterolemia despite statin therapy a number of dif-
ferent approaches is possible. Niacin/laropiprant, ezetimibe 
or a bile acid binding compound can be added, since all 
provide further LDL-cholesterol reduction by approximately 
20% (which may vary considerably in individual patients). 
Define lipid goals
Drug therapya
Lifestyle modification
Isolated
Hypertriglyceridemiab
Fibrate;
ω-3-FA;
ERN/LRPT
Combined Hyperlipoproteinemia
LDL-hypercholesterolemia
Statinc
Statin +
Ezetimibe 
Statin +
Colesev. 
Statin +
ERN/LRPT 
Statin +
ω-3-FA 
(Statin + Fibrated)
Figure 1 The figure describes a possible algorithm for treating patients with different forms of dyslipidemia.
Notes: ain patients with established cardiovascular disease lifestyle modification and drug therapy will usually be implemented simultaneously; bisolated hypertriglyceridemia 
refers to a LDL-cholesterol  100 mg/dL and elevated triglycerides; fibrates, omega-3 fatty acids or ERN/LRPT may be used if lifestyle modification is not sufficient; in selected 
patients combination therapy may be necessary; cif LDL-cholesterol goal is not achieved the statin dose may be increased or switched to a more potent statin; dstatin/fibrate 
combination is associated with significant side effects and should therefore be only used in selected patients.
Abbreviations: ω-3-FA, omega-3 fatty acids; eRN/LRPT, extended release niacin/laropiprant.Vascular Health and Risk Management 2009:5 907
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While niacin and bile acid-binding substances have been proven 
to reduce CHD events, no such data are available for ezetimibe. 
On the other hand, ezetimibe is associated with fewer side effects 
compared to niacin and bile acid-binding substances.
Whether or not niacin/laropiprant is a treatment option for 
patients with elevated lipoprotein(a) remains to be determined. 
Although niacin may decrease lipoprotein(a) by up to 30%, it is 
unclear whether such a modification mediates a clinical benefit. 
However, in patients with elevated lipoprotein(a) and recurrent 
cardiovascular events despite optimal treatment of all other 
risk factors niacin/laropiprant may be a treatment option.
Although niacin has been shown to mediate beneficial 
effects on cardiovascular outcome if given in monotherapy 
or in combination with other lipid-altering drugs, including 
statins, no published study has used high-dose statin mono-
therapy as a comparator. Thus, strictly speaking the additional 
benefit of niacin has not been shown in patients on statin 
therapy. Therefore its use should be restricted to patients at 
high-risk until further data are available.
Several large outcome studies will evaluate whether niacin 
therapy can reduce cardiovascular events. These studies 
will be published in 2011 or 2012. The hypothesis of AIM-
HIGH is that combination antidyslipidemic therapy (niacin 
with simvastatin) will be superior to statin monotherapy 
(simvastatin) when used as secondary prevention in reducing 
long-term clinical events in patients with documented vascular 
disease and atherogenic dyslipidemia. About 3300 patients 
will be randomized to receive simvastatin monotherapy or 
simvastatin with niacin.
In another study (HPS2-THRIVE) it will be evaluated 
whether the combination of niacin and laropiprant prevents 
myocardial infarctions, stroke or revascularization proce-
dures in patients with existing vascular disease. Approxi-
mately 25,000 patients will be evaluated, including more 
than 7000 diabetic patients.
Disclosures
KGP has received travel rants, speaking fees or research 
support form AstraZeneca, Bayer, Genzyme, MSD, Novartis, 
Sanofi-Aventis, and Schering-Plough.
References
  1.  Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates 
in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206.
  2.  Hansson GK. Inflammation, atherosclerosis and coronary artery disease. 
N Engl J Med. 2005;352:1685–1695.
  3.  Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ 
(CTT) Collaborators. Efficacy and safety of cholesterol-lowering 
treatment:prospective meta-analysis of data from 90,056 participants 
in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
  4.  Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, 
Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy 
in 18,686 people with diabetes in 14 randomised trials of statins:a 
meta-analysis. Lancet. 2008;371:117–125.
  5.  Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical 
trials for the National Cholesterol Education Program Adult Treatment 
Panel III guidelines. Circulation. 2004;110:227–239.
  6.  Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on 
cardiovascular disease prevention in clinical practice: executive sum-
mary: Fourth Joint Task Force of the European Society of Cardiology 
and Other Societies on Cardiovascular Disease Prevention in Clinical 
Practice. Eur Heart J. 2007;28:2375–2414.
  7.  American Diabetes Association. Standards of Medical Care in Diabetes –   
2009. Diab Care. 2009;32 S1:S13–S61.
  8.  Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum 
cholesterol in man. Arch Biochem. 1955;54:558–559.
  9.  Vogt A, Kassner U, Hostalek U, et al. Evaluations of safety and toler-
ability of prolonged-release nicotinic acid in a usual care setting: the 
NAUTILUS Study. Curr Med Res Opin. 2006;22:417–425.
10.  Shepherd J, Packard DJ, Patsch JR, et al. Effects of nicotinic acid 
therapy on plasma high density lipoprotein subfraction distribution 
and composition and on apolipoptotein A metabolism. J Clin Invest. 
1979;63:858–867.
11.  Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 
1999;341:498–511.
12.  Coronary Drug Project Research Group. Clofibrate and niacin in coro-
nary heart disease. JAMA. 1975;231:360.
13.  Carlson LA Rosenhamer G. Reduction of mortality in the Stockholm Isch-
aemic Heart Disease Secondary Prevention Study by combined treatment 
with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405.
14.  McKenney JM, Jones PH, Bays HE, et al. Comparative effects on 
lipid levels of combination therapy with a statin and extended-release 
niacin or ezetimibe versus a statin alone (the COMPELL study). 
Atherosclerosis. 2007;192:432–437.
15.  Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an 
extended-release niacin (Niaspan):a long-term study. Am J Cardiol. 
1998;82:74U–81U.
16.  Kamanna VS, Ganji SH, Kashyap ML. Niacin:an old drug rejuvenated. 
Curr Atheroscler Rep. 2009;11:45–51.
17.  Benyo Z, Gille A, Kero J. GPR109A (PUMA-G/HM74A) mediates 
nicotinic acid-induced flushing. J Clin Invest. 2005;115:3634–2640.
18.  Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty 
acids. Acta Med Scand. 1962;172:641–645.
19.  Carlson LA. Nicotinic acid: the broad spectrum lipid drug. A 50th 
anniversary review. J Intern Med. 2005;258:94–114.
20.  Van JT, Pan J, Wasty T, et al. Comparison of extended-release niacin 
and atorvastatin monotherapies and combination treatment of the athero-
genic lipid profile in diabetes mellitus. Am J Cardiol. 2002;89:1306.
21.  Davidson MH. Novel nonstatin strategies to lower low-density lipo-
protein cholesterol. Curr Atheroscler Rep. 2009;11:67–70.
22.  Brown BG, Zhao XQ Chait A, et al. Simvastatin and niacin, antioxidant 
vitamins, or the combination for the prevention of coronary disease. 
N Engl J Med. 2001;345:1583–1592.
23.  Canner PL, Berge KH, Wenger NK, et al. Fifteen year mortality in 
coronary drug project patients: long-term benefit with niacin. J Am 
Coll Cardiol. 1986;8:1245.
24.  Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of 
combined colestipol-niacin therapy on coronary atherosclerosis and 
coronary venous bypass grafts. JAMA. 1987;257:3233–3240.
25.  Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol 
(ARBITER) 2: a double-blind, placebo-controlled study of extended-
release niacin on atherosclerosis progression in secondary prevention 
patients treated with statins. Circulation. 2004;110:3512–3517.
26.  Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of com-
bination statin and extended-release niacin on carotid intima-media 
thickness: ARBITER 3. Curr Med Res Opin. 2006;11:2243–2250.Vascular Health and Risk Management 2009:5
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
908
Parhofer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27.  Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a 
therapeutic target:a systematic review. JAMA. 2007;298:786–798.
28.  Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of 
simvastatin plus niacin in patients with coronary artery disease and 
low high-density lipoprotein cholesterol (The HDL Atherosclerosis 
Treatment Study). Am J Cardiol. 2004;93:307–312.
29.  Rubenfire M. Safety and compliance with once-daily niacin 
extended-release/lovastatin as initial therapy in the Impact of Medical 
Subspeciality on Patient Compliance to Treatment (IMPACT) Study. 
Am J Cardiol. 2004;94:306–311.
30.  Morrow JD, Awad JA, Oates JA, et al. Identification of skin as a major 
site of prostaglandin D2 release following oral administration of niacin 
in humans. J Invest Dermatol. 1992;98:812–815.
31.  Ishida H, Masuhio Y, Fukushima A, et al. Identification and character-
ization of novel isoforms of human DP-1:DP-1 (alpha) regulates the 
transcriptional activity of E2F1 as well as cell cycle progression in a 
dominant-negative manner. J Biol Chem. 2005;280:24642–24648.
32.  Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 
receptor 1 suppresses nicotinic acid-induced vasodilation in mice and 
humans. Proc Natl Acad Sci U S A. 2006;103:6682–6687.
33.  Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, 
Campbell JR. Effect of two aspirin pretreatment regimens on niacini-
nduced cutaneous reactions. J Gen Intern Med. 1997;12:591–596.
34.  Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J, 
et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol 
Ther. 1982;31:478–482.
35.  Dunn RT, For MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and 
ibuprofen reduce the cutaneous reactions following niacin administra-
tion. Am J Ther. 1995;2:478–480.
36.  Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and 
tolerability of once-daily niacin for the treatment of dyslipidemia 
associated with type 2 diabetes: results of the assessment of diabetes 
control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 
2002;162:1568.
37.  Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin 
by glycemic status in patients with healed myocardial infarction (from 
the Coronary Drug Project). Am J Cardiol. 2005;95:254–257.
38.  Dean BJ, Chang S, Silva Elipe MV, et al. Metabolism of MK-0524, 
a prostaglandin D2 receptor 1 antagonist, in microsomes and hepa-
tocytes from preclinical species and humans. Drug Metab Dispos. 
2007;35:283–292.
39.  Sturino CF, O’Neill G, Lachance N, et al. Discovery of a potent and 
selective PGD2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-
5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]-acetic acid 
(MK-0524). J Med Chem. 2007;50:794–806.
40.  Van Hecken A, Depré M, De Lepeleire I, et al. The effect of MK-0524, 
a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced 
nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol. 
2007;63:135–141.
41.  Bindhu K, Maria M, Scott B, et al. Absorption, metabolism, and excre-
tion of [14C]MK-0524, a prostaglandin D2 receptor antagonist, in 
humans. Drug Metab Dispos. 2007;35:1196.
42.  Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmaco-
dynamics, and safety of a prostaglandin D2 receptor antagonist. Clin 
Pharmacol Ther. 2008;83:840–847.
43.  Dishy V, Liu F, Ebel DL, Atiee GJ, et al. Effects of aspirin when added to 
the prostaglandin D2 receptor antagonist laropiprant on niacin-induced 
flushing symptoms. J Clin Pharmacol. 2009;49:416–422.
44.  Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced “flush” 
involves release of prostaglandin D2 from mast cells and serotonin 
from platelets: evidence from human cells in vitro and an animal model. 
J Pharm Exp Ther. 2008;327:665–672.
45.  Felts AS. Molecule of the month. TREDAPTIVE (nicotinic acid/
laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, 
HDL-C and triglycerides. Curr Top Med Chem. 2008;14:1310.
46.  Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of 
extended-release niacin/laropiprant versus gradually titrated niacin 
extended-release in patients with dyslipidemia with and without isch-
emic cardiovascular disease. Am J Cardiol. 2009;104:74–81.
47.  Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release 
niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. 
Cardiology. 2009;114:192–198.
48.  McKenney J, Bays H, Koren M, et al. Safety profile of extended-
release niacin/laropiprant in patients with dyslipidemia. Abstracts 77th 
Congress of the European Atherosclerosis Society. Atherosclerosis 
Suppl. 2008;9(1):194–195.
49.  Maccubbin D, Bays HE, Olsson Ag, et al. Lipid-modifying efficacy 
and tolerability of extended-release niacin/laropiprant in patients with 
primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 
2008;62:1959–1970.
50.  Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of 
co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. 
Br J Cardiol. 2009;16:90–97.
51.  Paolini JF, Mitchel YB, Reyes R, Effects of laropiprant on nicotinic 
acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 
2008;101:625–630.
52.  Bays HE, Maccubbin D, Meehan AG, et al. Blood pressure-lowering 
effects of extended-release niacin alone and extended-release niacin/
laropiprant combination: a post hoc analysis of a 24-week, placebo-
controlled trial in dyslipidemic patients. Clin Ther. 2009;31:115–122.
53. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? 
Int J Clin Pract. 2009;63:151–159.